Abstract:We appreciate the comments regarding our recent manuscript on assessing the value of left ventricular (LV) midwall late gadolinium enhancement (LGE) in predicting sudden cardiac death (SCD) endpoint in patients with non-ischaemic dilated cardiomyopathy (NICM)1 and raising the controversial issue regarding implantable cardioverter defibrillator (ICD) placement in the treatment of NICM patients with presence of LV midwall LGE. First, we selected articles with diagnostic criteria of NICM in accordance with the World Health Organization recommendation2; therefore, all patients with the significant primary valvular disease were excluded. Additionally, medical treatment has been provided in Table 1. Moreover, the proportion of NICM patients with New York Heart Association class II to IV and left anterior branch block is 86.7% (1556/1796) and 26.2% (370/1414), respectively, according to the available data. In the study of Køber et al., 3 among patients with NICM and LV ejection fraction (EF) (≤35%), who were randomly assigned to an ICD or clinical care, the investigators found that an appropriate ICD therapy cannot be translated to lower all-cause mortality. Thus, it is imperial to precisely identify high-risk patients with NICM who are most likely to benefit from ICD therapy. In our study, the proportion of SCD endpoint is similar between subgroup with LV dysfunction (<35%), and with the LVEF ≥ 35%, the negative predictive value of LV midwall LGE on predicting SCD event is excellent and the numbers of ICD required to prevent one major event based on the presence of LV midwall LGE are low, which implied that NICM patients with LV midwall LGE could likely benefit from ICD placement regardless of LVEF. This conclusion was based on presented data and subgroup analysis by LVEF. We agree that the clinical decision of ICD placement is currently based on the evaluation of LVEF. However, some patients with NICM underwent LV reverse remodelling after the guideline-directed medical therapy.4 In these cases, many patients with the dysfunction could recover. Therefore, it certainly needs better biomarkers of risk stratification in patients with NICM. We agree that the ICD placement can lead to short-term and long-term complications. However, the focus of our discussion of the present study is on the risk of SCD occurrence, and this conclusion provides potential clinical guidance for ICD placement. Thereby, we wish to point out the SCD predictive value of LV midwall LGE in patients with NICM. Rather, more prospective studies are needed to assess whether LV midwall LGE could be the main criterion of ICD treatment.

Very long-term follow-up data of non-ischemic idiopathic dilated cardiomyopathy after beta-blocker therapy: recurrence of left ventricular dysfunction and predictive value of 123I-metaiodobenzylguanidine scintigraphy

Peripheral Endothelial Function May Predict the Effectiveness of Beta-Blocker Therapy in Patients with Idiopathic Dilated Cardiomyopathy.

Recurrence of Left Ventricular Dysfunction in Patients With Restored Idiopathic Dilated Cardiomyopathy

Prognostic Value of Mid-Term Cardiovascular Magnetic Resonance Follow-Up in Patients with Non-Ischemic Dilated Cardiomyopathy: a Prospective Cohort Study

Clinical Outcome of Patients with Previous Myocardial Infarction and Left Ventricular Dysfunction Assessed with Myocardial (99M)tc-Mibi SPECT and (18)F-FDG PET.

The Prognostic Impact of Follow-up Cardiac MIBG Imaging on LV trajectory After Acute Decompensation

Cardiac sympathetic innervation, assessed with 123I-MIBG SPECT, predicts left ventricular function improvement in patients with newly diagnosed dilated cardiomyopathy

Abstract 11983: Prolonged Coronary Arterial Phase and Recurrent Ischemia Are Hallmarks of Repeat Heart Failure and Sudden Cardiac Death in Patient with Dilated Cardiomyopathy and Patent Coronary Arteries an Angiographic and Machine Learning Analysis

Abstract 15126: Myocardial Tissue Reverse Remodeling After Guideline-directed Medical Therapy in Idiopathic Dilated Cardiomyopathy

Long-term follow-up of the TRED-HF trial

Reply To: Left Ventricular Midwall Fibrosis As a Predictor of Sudden Cardiac Death in Non‐ischaemic Dilated Cardiomyopathy: a Meta‐analysis

The Significance of Cardiac Sympathetic Nervous System Abnormality in the Long-Term Prognosis of Patients with a History of Ventricular Tachyarrhythmia

Prognostic significance of left ventricular dyssynchrony by phase analysis of gated SPECT in medically treated patients with dilated cardiomyopathy.

Abstract 13677: Usefulness of 2-year Iodine-123 Metaiodobenzylguanidine-based Risk Model for the Post-discharge Risk Stratification in Acute Decompensated Heart Failure Patients With Preserved Left Ventricular Ejection Fraction

Myocardial Tissue Reverse Remodeling after Guideline-directed Medical Therapy in Idiopathic Dilated Cardiomyopathy.

Prognostic value of multiple cardiac magnetic resonance imaging parameters in patients with idiopathic dilated cardiomyopathy

Strain Parameters for Predicting the Prognosis of Non‐ischemic Dilated Cardiomyopathy Using Cardiovascular Magnetic Resonance Tissue Feature Tracking

Long-Term Prognostic Value of Combined Free Triiodothyronine and Late Gadolinium Enhancement in Nonischemic Dilated Cardiomyopathy

The prognostic impact of cardiac Metaiodobenzylguanidine imaging related to left ventricular geometry in patients with acute decompensated heart failure: a prospective study

Incremental Value of Left Ventricular Mechanical Dyssynchrony Assessment by Nitrogen-13 Ammonia ECG-Gated PET in Patients With Coronary Artery Disease

Non‐dilated left ventricular cardiomyopathy vs. dilated cardiomyopathy: clinical background and outcomes